Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rand Arafeh

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Seminars in Cancer Biology|February 12, 2019
PIK3CA in cancer: The past 30 yearsRand Arafeh, Yardena Samuels
Nature Reviews. Cancer|October 29, 2024
The present and future of the Cancer Dependency MapRand Arafeh, Tsukasa Shibue, Joshua M Dempster, et al.
Iscience|October 28, 2022
NRas activity is regulated by dynamic interactions with nanoscale signaling clusters at the plasma membraneOren Yakovian, Julia Sajman, Michal Alon, et al.
Cancer Research|December 23, 2020
MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self NanoclustersOren Yakovian, Julia Sajman, Rand Arafeh, et al.
Scientific Reports|November 29, 2017
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cellsRand Arafeh, Karen Flores, Alona Keren-Paz, et al.
Scientific Reports|March 13, 2019
Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cellsRand Arafeh, Karen Flores, Alona Keren-Paz, et al.
Oncotarget|March 14, 2019
Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanomaMichal Alon, Rand Arafeh, Joo Sang Lee, et al.
Oncotarget|August 23, 2018
CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanomaMichal Alon, Rand Arafeh, Joo Sang Lee, et al.
Oncotarget|March 10, 2015
miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cellsZaidoun Salah, Rand Arafeh, Vadim Maximov, et al.
Pigment Cell & Melanoma Research|September 25, 2019
A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanomaAdi Nagler, David W Vredevoogd, Michal Alon, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Seminars in Cancer Biology|February 12, 2019
PIK3CA in cancer: The past 30 yearsRand Arafeh, Yardena Samuels
Nature Reviews. Cancer|October 29, 2024
The present and future of the Cancer Dependency MapRand Arafeh, Tsukasa Shibue, Joshua M Dempster, et al.
Iscience|October 28, 2022
NRas activity is regulated by dynamic interactions with nanoscale signaling clusters at the plasma membraneOren Yakovian, Julia Sajman, Michal Alon, et al.
Cancer Research|December 23, 2020
MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self NanoclustersOren Yakovian, Julia Sajman, Rand Arafeh, et al.
Scientific Reports|November 29, 2017
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cellsRand Arafeh, Karen Flores, Alona Keren-Paz, et al.
Scientific Reports|March 13, 2019
Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cellsRand Arafeh, Karen Flores, Alona Keren-Paz, et al.
Oncotarget|March 14, 2019
Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanomaMichal Alon, Rand Arafeh, Joo Sang Lee, et al.
Oncotarget|August 23, 2018
CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanomaMichal Alon, Rand Arafeh, Joo Sang Lee, et al.
Oncotarget|March 10, 2015
miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cellsZaidoun Salah, Rand Arafeh, Vadim Maximov, et al.
Pigment Cell & Melanoma Research|September 25, 2019
A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanomaAdi Nagler, David W Vredevoogd, Michal Alon, et al.
Pageof 2